Wikipedia

Performance-enhancing substance

(Redirected from Performance-enhancing drugs)

Performance-enhancing substances (PESs), also known as performance-enhancing drugs (PEDs),[1] are substances that are used to improve any form of activity performance in humans.

Many substances, such as anabolic steroids, can be used to improve athletic performance and build muscle, which in most cases is considered cheating by organized athletic organizations. This usage is often referred to as doping. Athletic performance-enhancing substances are sometimes referred to as ergogenic aids.[2][3] Cognitive performance-enhancing drugs, commonly called nootropics,[4] are sometimes used by students to improve academic performance. Performance-enhancing substances are also used by military personnel to enhance combat performance.[5]

Definition

edit

The classifications of substances as performance-enhancing substances are not entirely clear-cut and objective. As in other types of categorization, certain prototype performance enhancers are universally classified as such (like anabolic steroids), whereas other substances (like vitamins and protein supplements) are virtually never classified as performance enhancers despite their effects on performance. As is usual with categorization, there are borderline cases; caffeine, for example, is considered a performance enhancer by some but not others.[6]

Types

edit

The phrase has been used to refer to several distinct classes of drugs:

Anabolic steroids

edit
Main article: Anabolic steroid

Anabolic steroids are synthetically derived from testosterone and modified to have greater anabolic effects.[7] They work by increasing the concentration of nitrogen in the muscle which inhibits catabolic glucocorticoid binding to muscle.[8] This ultimately prohibits the breakdown of muscle and preserves muscle mass.[9] Examples of anabolic steroids include: oxandrolone, stanozolol and nandrolone.[7] Anabolic steroids can be taken through a transdermal method, orally, or through injection. Injectable forms of the steroid are the most potent and long-lasting.[10] In general, potential side effects include: muscle hypertrophy, acne, hypertension, elevated cholesterol, thrombosis, decreased high-density lipoproteins, altered libido, hepatic carcinoma, cholestasis, peliosis hepatitis, septic arthritis, Wilm's tumor, psychosis, aggression, addiction, and depression.[11] Potential side effects specifically in males include: male pattern baldness, oligospermia, prostate hypertrophy, testicular atrophy, and prostate cancer.[12] Potential side specifically in females include: hirsutism, uterine atrophy, amenorrhea, breast atrophy, and thickening of vocal cords (voice deepening).[12] Urine samples are tested to determine the ratio of testosterone glucuronide to epitestosterone glucuronide, which should be 3:1. Any ratio of 4:1 or greater is considered a positive test.[13] The 1988 Anti-Drug Abuse Act and 1990 Anabolic Steroid Act both deemed anabolic steroids as an illegal substance when not used for disease treatment.[10]

Stimulants

edit
Main article: Stimulant

Stimulants improve focus and alertness. Low (therapeutic) doses of dopaminergic stimulants (e.g., reuptake inhibitors and releasing agents) also promote mental and athletic performance, as cognitive enhancers and ergogenic aids respectively, by improving muscle strength and endurance while decreasing reaction time and fatigue.[3][14][15] Stimulants are commonly used in lengthy exercises that require short bursts (e.g., tennis, team sports, etc.).[16] Stimulants work by increasing catecholamine levels and agonistic activity at the adrenergic receptors.[17] Examples of stimulants include caffeine,[2] ephedrine, methylphenidate and amphetamine.[3][14][15][18][19] Potential side effects include hypertension, insomnia, headaches, weight loss, arrhythmia, tremors, anxiety, addiction, and strokes.[20] Some stimulants are allowed in competitive sports and are widely accessible, though may also be monitored by the World Anti-Doping Agency (WADA), such as caffeine.[2] Others are banned as per the WADA (e.g., cocaine, amphetamines, ephedrine, etc.).[21][22]

Ergogenic aids

edit

Ergogenic aids, or athletic performance-enhancing substances, include a number of drugs with various effects on physical performance. Drugs such as amphetamine and methylphenidate increase power output at constant levels of perceived exertion and delay the onset of fatigue,[18][19][23] among other athletic-performance-enhancing effects;[3][14][15] bupropion also increases power output at constant levels of perceived exertion, but only during short-term use.[23]

Examples

edit
Main articles: Human growth hormone, Creatine, and Beta-Hydroxy-Beta-methylbutyrate
  • Creatine: one of the most popular nutritional supplements, it contributes to 400 million dollars in sales globally every year.[24] It is a nonessential amino acid that helps to improve an athlete's performance during short-term, high intensity exercises such as weightlifting.[25] Supplementation of creatine increases skeletal muscle creatine levels, this boosts performance by increasing the rate at which adenosine triphosphate can be replenished from adenosine diphosphate, thereby increasing maximal power output.[24] Potential side effects include gastrointestinal cramps, weight gain, fatigue, and diarrhea.[26] Creatine is currently not recognized as a prohibited substance and can be purchased as a legal dietary supplement.[27]
  • β-hydroxy β-methylbutyrate, a metabolite of leucine also used as a supplement, has positive effects on lean muscle mass, possibly through a decrease in muscle catabolism.[28]
  • Human Growth Hormone (hGH): endogenous hormone that can help decrease fat mass while increasing lean body mass.[29] hGH is one of the most commonly used substances among professional athletes because it has a small window for detection.[29] It works by promoting the release of IGF-1, insulin-like growth factor, the release of which has anabolic effects on the body.[30] Potential side effects include: cardiomyopathy, diabetes, renal failure, and hepatitis.[31] If not prescribed by a professional, it is a banned substance in competition per WADA.[22] Despite its small window for detection, two primary methods of testing have been developed for hGH, one being an isoform test which detects changes in growth hormone structure in the blood,[32] and the markers test, which detects changes in serum protein ratios.[32]

Adaptogens

edit
Main article: Adaptogen

Adaptogens are plants that support health through nonspecific effects, neutralize various environmental and physical stressors while being relatively safe and free of side effects.[33] As of 2008, the position of the European Medicines Agency was that "The principle of an adaptogenic action needs further clarification and studies in the pre-clinical and clinical area. As such, the term is not accepted in pharmacological and clinical terminology that is commonly used in the EU."[34]

Actoprotectors

edit
Main article: Actoprotector

Actoprotectors or synthetic adaptogens are compounds that enhance an organism's resilience to physical stress without increasing heat output. Actoprotectors are distinct from other doping compounds in that they increase physical and psychological resilience via non-exhaustive action. Actoprotectors such as bemethyl and bromantane have been used to prepare athletes and enhance performance in Olympic competition.[35][36] However, only bromantane has been placed on the World Anti-Doping Agency's banned list.[36]

Nootropics

edit
Main article: Nootropic

Nootropics, or "cognition enhancers", are substances that are claimed to benefit overall cognition by improving memory (e.g., increasing working memory capacity or updating) or other aspects of cognitive control (e.g., inhibitory control, attentional control, attention span, etc.).[4][37]

CNS agents

edit

Painkillers

edit
Main article: Analgesic

Allows performance beyond the usual pain threshold. Some painkillers raise blood pressure, increasing oxygen supply to muscle cells. Painkillers used by athletes range from common over-the-counter medicines such as NSAIDs (such as ibuprofen) to powerful prescription narcotics.

Sedatives and anxiolytics

edit
Main articles: Sedative and Anxiolytic

Sedatives and anxiolytics are used in sports like archery which require steady hands and accurate aim, and also to overcome excessive nervousness or discomfort for more dangerous sports. Diazepam, nicotine, and propranolol are common examples. Ethanol, the most commonly used substance by athletes, can be used for cardiovascular improvements though has significant detrimental effects. Ethanol was formerly banned by WADA during performance for athletes performing in aeronautics, archery, automobile, karate, motorcycling and powerboating, but was taken off the ban list in 2017. It is detected by breath or blood testing. Cannabis is banned at all times for an athlete by WADA, though performance-enhancing effects have yet to be studied. Cannabis and nicotine are detected through urine analysis.[2][38]

Blood boosters

edit
Main article: Blood doping

Blood doping agents increase the oxygen-carrying capacity of blood beyond the individual's natural capacity.[39] They are used in endurance sports like long-distance running, cycling, and Nordic skiing. Recombinant human erythropoietin (rhEPO) is one of the most widely known drugs in this class.[28][39] The Athlete Biological Passport is the only indirect testing method for detection of blood doping.

Erythropoietin

edit
Main article: Erythropoietin

Erythropoietin, or EPO, is a hormone that helps increase the production of red blood cells which increases the delivery of oxygen to muscles.[40] It is commonly used among endurance athletes such as cyclists.[40] It functions by protecting red blood cells against destruction whilst simultaneously stimulating bone marrow cells to produce more red blood cells.[41] Potential side effects include: dehydration and an increase in blood viscosity which could result in a pulmonary embolism or stroke.[42] Per the WADA, it is a banned substance.[22] Urine samples can be tested via electrophoresis, and blood samples via indirect markers.[example needed][43]

Gene doping

edit
Main article: Gene doping

Gene doping agents are a relatively recently described class of athletic performance-enhancing substances.[28] These drug therapies, which involve viral vector-mediated gene transfer, are not known to currently be in use as of 2020.[28][44]

Prohormones

edit
Main article: Prohormone

Also known as anabolic steroid precursors, they promote lean body mass.[45] Once in the body, these precursors are converted to testosterone and increase endogenous testosterone.[46] The desired effects of steroid precursors however, are often not seen as they do not bind well to androgen receptors.[46] Examples of prohormones include norandrostendione, androstenediol, and dehydroepiandrosterone (DHEA).[45] These steroids have little desired effect compared to anabolic steroids, but have the same side effects.[47] Androstenedione in 2005 became classified as a controlled substance by WADA, however DHEA can still be obtained legally as an over-the-counter nutritional supplement.[48]

History

edit

While the use of PEDs has expanded in recent times, the practice of using substances to improve performance has been around since the Ancient Olympic Games.[49] In the Olympic Games of 668 BC, Charmis had consumed a diet consisting of dried figs which was thought, at the time, to be a significant factor in winning the 200-yard stade race.[50][39] Ancient Greek athletes at the time also incorporated substances such as wine and brandy into their training routines.[51] Stimulants derived from plants (e.g., Cola nitida, Bufotein, etc.) were used by the Roman gladiators to overcome injuries and fatigue.[52]

In the late 19th century as modern medicine and pharmacology were developing, PEDs saw an increase in use.[53] Supplements were now exclusively being used to enhance muscular work capacity.[53] The main substances being used included alcoholic drinks, caffeine, and mixtures created by the athletic trainers (e.g., strychnine tablets made of cocaine and brandy).[54]

In the 20th century, testosterone was isolated and characterized by scientists.[55] In 1941, the first record of synthesized testosterone use occurred when a horse was given testosterone which successfully improved its race performance.[56] Sports trainers soon after began advocating for testosterone use.[55] Images of bodybuilders with massive muscles began circulating which further perpetuated a desire among athletes to use testosterone.[57][55] In 1967, the first prohibited substance list and anti-doping measures were implemented at the 1968 Olympics.[39]

In the 1980s, the main PEDs were cortisone and anabolic steroids.[58] In 1988, the United States Congress established the Anti-Drug Abuse Act to criminalize the distribution and possession of non-medical anabolic steroids.[59] In 1999, WADA was formed to address the escalating use of substances in sports, particularly after the 1998 doping scandal in cycling.[59]

Risk factors

edit

Adolescents are the most vulnerable group when it comes to taking performance-enhancing substances.[60] This is in part due to the significance placed on physical appearance by this age group as well as feelings of invincibility combined with a lack of knowledge surrounding long-term consequences.[60] Studies have shown that the most common gendered risk factors include being an adolescent female dissatisfied with their body weight or an adolescent male who perceives larger body sizes as the ideal.[61] Having a negative body image or a history of depression can also be a significant risk factor.[61] These are further exacerbated by parental pressures surrounding appearance, media influence, and peer pressure.[60][52]

Studies show that adolescent males who engage with fitness magazines are twice as likely to use performance-enhancing substances.[52] Adolescents who partake in competitive sports are at a particularly high risk, with those involved in gridiron football, basketball, wrestling, baseball, and gymnastics at the top.[52]

Usage in sport

edit
Main article: Doping in sport

In sports, the term performance-enhancing drugs is popularly used in reference to anabolic steroids or their precursors (hence the colloquial term steroids); anti-doping organizations apply the term broadly.[62] Agencies such as the WADA and United States Anti-Doping Agency try to prevent athletes from using these drugs by performing drug tests. When medical exemptions are granted they are called therapeutic use exemptions.[63][64]

See also

edit

References

edit
  1. ^ "Effects of Performance-Enhancing Drugs | USADA". May 2019.
  2. ^ a b c d Pesta DH, Angadi SS, Burtscher M, Roberts CK (December 2013). "The effects of caffeine, nicotine, ethanol, and tetrahydrocannabinol on exercise performance". Nutrition & Metabolism. 10 (1): 71. doi:10.1186/1743-7075-10-71. PMC 3878772. PMID 24330705.
  3. ^ a b c d Liddle DG, Connor DJ (June 2013). "Nutritional supplements and ergogenic AIDS". Primary Care. 40 (2): 487–505. doi:10.1016/j.pop.2013.02.009. PMID 23668655. Amphetamines and caffeine are stimulants that increase alertness, improve focus, decrease reaction time, and delay fatigue, allowing for an increased intensity and duration of training ...
    Physiologic and performance effects [of amphetamines]
     • Amphetamines increase dopamine/norepinephrine release and inhibit their reuptake, leading to central nervous system (CNS) stimulation
     • Amphetamines seem to enhance athletic performance in anaerobic conditions 39 40
     • Improved reaction time
     • Increased muscle strength and delayed muscle fatigue
     • Increased acceleration
     • Increased alertness and attention to task    487-505&rft.date=2013-06&rft_id=info:doi/10.1016/j.pop.2013.02.009&rft_id=info:pmid/23668655&rft.aulast=Liddle&rft.aufirst=DG&rft.au=Connor, DJ&rfr_id=info:sid/en.wikipedia.org:Performance-enhancing substance" class="Z3988">
  4. ^ a b Frati P, Kyriakou C, Del Rio A, Marinelli E, Vergallo GM, Zaami S, et al. (January 2015). "Smart drugs and synthetic androgens for cognitive and physical enhancement: revolving doors of cosmetic neurology". Current Neuropharmacology. 13 (1): 5–11. doi:10.2174/1570159X13666141210221750. PMC 4462043. PMID 26074739. Cognitive enhancement can be defined as the use of drugs and/or other means with the aim to improve the cognitive functions of healthy subjects in particular memory, attention, creativity and intelligence in the absence of any medical indication. ... The first aim of this paper was to review current trends in the misuse of smart drugs (also known as Nootropics) presently available on the market focusing in detail on methylphenidate, trying to evaluate the potential risk in healthy individuals, especially teenagers and young adults.5-11&rft.date=2015-01&rft_id=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4462043#id-name=PMC&rft_id=info:pmid/26074739&rft_id=info:doi/10.2174/1570159X13666141210221750&rft.aulast=Frati&rft.aufirst=P&rft.au=Kyriakou, C&rft.au=Del Rio, A&rft.au=Marinelli, E&rft.au=Vergallo, GM&rft.au=Zaami, S&rft.au=Busardò, FP&rft_id=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4462043&rfr_id=info:sid/en.wikipedia.org:Performance-enhancing substance" class="Z3988">
  5. ^ Better Fighting Through Chemistry? The Role of FDA Regulation in Crafting the Warrior of the Future (Report). 8 March 2004. Archived from the original on 3 February 2016.
  6. ^ "Caffeine and Sports Performance". Vanderbilt.edu. Archived from the original on 29 February 2012. Retrieved 4 March 2012.
  7. ^ a b Kicman AT (June 2008). "Pharmacology of anabolic steroids". British Journal of Pharmacology. 154 (3): 502–521. doi:10.1038/bjp.2008.165. PMC 2439524. PMID 18500378.502-521&rft.date=2008-06&rft_id=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2439524#id-name=PMC&rft_id=info:pmid/18500378&rft_id=info:doi/10.1038/bjp.2008.165&rft.aulast=Kicman&rft.aufirst=A T&rft_id=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2439524&rfr_id=info:sid/en.wikipedia.org:Performance-enhancing substance" class="Z3988">
  8. ^ Ganesan K, Rahman S, Zito PM (2024). "Anabolic Steroids". StatPearls. StatPearls Publishing. PMID 29494025.
  9. ^ "Performance Enhancing Anabolic Steroid Abuse in Women". www.acog.org. Retrieved 12 April 2022.
  10. ^ a b Reardon CL, Creado S (14 August 2014). "Drug abuse in athletes". Substance Abuse and Rehabilitation. 5: 95–105. doi:10.2147/SAR.S53784. ISSN 1179-8467. PMC 4140700. PMID 25187752.95-105&rft.date=2014-08-14&rft_id=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4140700#id-name=PMC&rft.issn=1179-8467&rft_id=info:pmid/25187752&rft_id=info:doi/10.2147/SAR.S53784&rft.aulast=Reardon&rft.aufirst=Claudia L&rft.au=Creado, Shane&rft_id=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4140700&rfr_id=info:sid/en.wikipedia.org:Performance-enhancing substance" class="Z3988">
  11. ^ van Amsterdam J, Opperhuizen A, Hartgens F (June 2010). "Adverse health effects of anabolic–androgenic steroids". Regulatory Toxicology and Pharmacology. 57 (1): 117–123. doi:10.1016/j.yrtph.2010.02.001. PMID 20153798.117-123&rft.date=2010-06&rft_id=info:doi/10.1016/j.yrtph.2010.02.001&rft_id=info:pmid/20153798&rft.aulast=van Amsterdam&rft.aufirst=Jan&rft.au=Opperhuizen, Antoon&rft.au=Hartgens, Fred&rfr_id=info:sid/en.wikipedia.org:Performance-enhancing substance" class="Z3988">
  12. ^ a b Albano GD, Amico F, Cocimano G, Liberto A, Maglietta F, Esposito M, et al. (19 January 2021). "Adverse Effects of Anabolic-Androgenic Steroids: A Literature Review". Healthcare. 9 (1): 97. doi:10.3390/healthcare9010097. PMC 7832337. PMID 33477800.
  13. ^ Levy JL, Cabrera J, Thomas S, Brennan FH (2008). "Ergogenic Aids". The Sports Medicine Resource Manual. pp. 598–610. doi:10.1016/B978-141603197-0.10048-5. ISBN 978-1-4160-3197-0.598-610&rft.date=2008&rft_id=info:doi/10.1016/B978-141603197-0.10048-5&rft.isbn=978-1-4160-3197-0&rft.aulast=Levy&rft.aufirst=JL&rft.au=Cabrera, J&rft.au=Thomas, S&rft.au=Brennan, FH&rfr_id=info:sid/en.wikipedia.org:Performance-enhancing substance" class="Z3988">
  14. ^ a b c Parr JW (July 2011). "Attention-deficit hyperactivity disorder and the athlete: new advances and understanding". Clinics in Sports Medicine. 30 (3): 591–610. doi:10.1016/j.csm.2011.03.007. PMID 21658550. In 1980, Chandler and Blair47 showed significant increases in knee extension strength, acceleration, anaerobic capacity, time to exhaustion during exercise, pre-exercise and maximum heart rates, and time to exhaustion during maximal oxygen consumption (VO2 max) testing after administration of 15 mg of dextroamphetamine versus placebo. Most of the information to answer this question has been obtained in the past decade through studies of fatigue rather than an attempt to systematically investigate the effect of ADHD drugs on exercise. ... In 2008, Roelands and colleagues53 studied the effect of reboxetine, a pure NE reuptake inhibitor, similar to atomoxetine, in 9 healthy, well-trained cyclists. They too exercised in both temperate and warm environments. They showed decreased power output and exercise performance at both 18 and 30 degrees centigrade. Their conclusion was that DA reuptake inhibition was the cause of the increased exercise performance seen with drugs that affect both DA and NE (MPH, amphetamine, and bupropion).591-610&rft.date=2011-07&rft_id=info:doi/10.1016/j.csm.2011.03.007&rft_id=info:pmid/21658550&rft.aulast=Parr&rft.aufirst=JW&rfr_id=info:sid/en.wikipedia.org:Performance-enhancing substance" class="Z3988">
  15. ^ a b c Parker KL, Lamichhane D, Caetano MS, Narayanan NS (October 2013). "Executive dysfunction in Parkinson's disease and timing deficits". Frontiers in Integrative Neuroscience. 7: 75. doi:10.3389/fnint.2013.00075. PMC 3813949. PMID 24198770. Manipulations of dopaminergic signaling profoundly influence interval timing, leading to the hypothesis that dopamine influences internal pacemaker, or "clock," activity. For instance, amphetamine, which increases concentrations of dopamine at the synaptic cleft advances the start of responding during interval timing, whereas antagonists of D2 type dopamine receptors typically slow timing;... Depletion of dopamine in healthy volunteers impairs timing, while amphetamine releases synaptic dopamine and speeds up timing.
  16. ^ "Office of Dietary Supplements – Dietary Supplements for Exercise and Athletic Performance". ods.od.nih.gov. Retrieved 12 April 2022.
  17. ^ Farzam K, Faizy RM, Saadabadi A (2022), "Stimulants", StatPearls, Treasure Island (FL): StatPearls Publishing, PMID 30969718, retrieved 12 April 2022
  18. ^ a b Roelands B, de Koning J, Foster C, Hettinga F, Meeusen R (May 2013). "Neurophysiological determinants of theoretical concepts and mechanisms involved in pacing". Sports Medicine. 43 (5): 301–311. doi:10.1007/s40279-013-0030-4. PMID 23456493. S2CID 30392999.301-311&rft.date=2013-05&rft_id=https://api.semanticscholar.org/CorpusID:30392999#id-name=S2CID&rft_id=info:pmid/23456493&rft_id=info:doi/10.1007/s40279-013-0030-4&rft.aulast=Roelands&rft.aufirst=B&rft.au=de Koning, J&rft.au=Foster, C&rft.au=Hettinga, F&rft.au=Meeusen, R&rfr_id=info:sid/en.wikipedia.org:Performance-enhancing substance" class="Z3988">
  19. ^ a b Rattray B, Argus C, Martin K, Northey J, Driller M (March 2015). "Is it time to turn our attention toward central mechanisms for post-exertional recovery strategies and performance?". Frontiers in Physiology. 6: 79. doi:10.3389/fphys.2015.00079. PMC 4362407. PMID 25852568. Aside from accounting for the reduced performance of mentally fatigued participants, this model rationalizes the reduced RPE and hence improved cycling time trial performance of athletes using a glucose mouthwash (Chambers et al., 2009) and the greater power output during a RPE matched cycling time trial following amphetamine ingestion (Swart, 2009). ... Dopamine stimulating drugs are known to enhance aspects of exercise performance (Roelands et al., 2008)
  20. ^ Reardon CL, Factor RM (May 2016). "Considerations in the Use of Stimulants in Sport". Sports Medicine (Auckland, N.Z.). 46 (5): 611–617. doi:10.1007/s40279-015-0456-y. ISSN 1179-2035. PMID 26712509. S2CID 27551597.611-617&rft.date=2016-05&rft.issn=1179-2035&rft_id=https://api.semanticscholar.org/CorpusID:27551597#id-name=S2CID&rft_id=info:pmid/26712509&rft_id=info:doi/10.1007/s40279-015-0456-y&rft.aulast=Reardon&rft.aufirst=Claudia L.&rft.au=Factor, Robert M.&rft_id=https://pubmed.ncbi.nlm.nih.gov/26712509/&rfr_id=info:sid/en.wikipedia.org:Performance-enhancing substance" class="Z3988">
  21. ^ Cappelletti S, Daria P, Sani G, Aromatario M (January 2015). "Caffeine: Cognitive and Physical Performance Enhancer or Psychoactive Drug?". Current Neuropharmacology. 13 (1): 71–88. doi:10.2174/1570159X13666141210215655. ISSN 1570-159X. PMC 4462044. PMID 26074744.71-88&rft.date=2015-01&rft_id=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4462044#id-name=PMC&rft.issn=1570-159X&rft_id=info:pmid/26074744&rft_id=info:doi/10.2174/1570159X13666141210215655&rft.aulast=Cappelletti&rft.aufirst=Simone&rft.au=Daria, Piacentino&rft.au=Sani, Gabriele&rft.au=Aromatario, Mariarosaria&rft_id=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4462044&rfr_id=info:sid/en.wikipedia.org:Performance-enhancing substance" class="Z3988">
  22. ^ a b c "The Prohibited List". World Anti-Doping Agency. Retrieved 12 April 2022.
  23. ^ a b Roelands B, De Pauw K, Meeusen R (June 2015). "Neurophysiological effects of exercise in the heat". Scandinavian Journal of Medicine & Science in Sports. 25 (Suppl 1): 65–78. doi:10.1111/sms.12350. PMID 28633657. S2CID 22782401. Physical fatigue has classically been attributed to peripheral factors within the muscle (Fitts, 1996), the depletion of muscle glycogen (Bergstrom & Hultman, 1967) or increased cardiovascular, metabolic, and thermoregulatory strain (Abbiss & Laursen, 2005; Meeusen et al., 2006b). In recent decennia however, it became clear that the central nervous system plays an important role in the onset of fatigue during prolonged exercise (Klass et al., 2008), certainly when ambient temperature is increased ... 5-HT, DA, and NA have all been implicated in the control of thermoregulation and are thought to mediate thermoregulatory responses, certainly since their neurons innervate the hypothalamus (Roelands & Meeusen, 2010). ... This indicates that subjects did not feel they were producing more power and consequently more heat. The authors concluded that the "safety switch" or the mechanisms existing in the body to prevent harmful effects are overridden by the drug administration (Roelands et al., 2008b). Taken together, these data indicate strong ergogenic effects of an increased DA concentration in the brain, without any change in the perception of effort. ... The combined effects of DA and NA on performance in the heat were studied by our research group on a number of occasions. ... the administration of bupropion (DA/NA reuptake inhibitor) significantly improved performance. Coinciding with this ergogenic effect, the authors observed core temperatures that were much higher compared with the placebo situation. Interestingly, this occurred without any change in the subjective feelings of thermal sensation or perceived exertion. Similar to the methylphenidate study (Roelands et al., 2008b), bupropion may dampen or override inhibitory signals arising from the central nervous system to cease exercise because of hyperthermia, and enable an individual to continue maintaining a high power output65-78&rft.date=2015-06&rft_id=https://api.semanticscholar.org/CorpusID:22782401#id-name=S2CID&rft_id=info:pmid/28633657&rft_id=info:doi/10.1111/sms.12350&rft.aulast=Roelands&rft.aufirst=B&rft.au=De Pauw, K&rft.au=Meeusen, R&rft_id=https://doi.org/10.1111%2Fsms.12350&rfr_id=info:sid/en.wikipedia.org:Performance-enhancing substance" class="Z3988">
  24. ^ a b Butts J, Jacobs B, Silvis M (23 October 2017). "Creatine Use in Sports". Sports Health. 10 (1): 31–34. doi:10.1177/1941738117737248. ISSN 1941-7381. PMC 5753968. PMID 29059531.31-34&rft.date=2017-10-23&rft_id=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5753968#id-name=PMC&rft.issn=1941-7381&rft_id=info:pmid/29059531&rft_id=info:doi/10.1177/1941738117737248&rft.aulast=Butts&rft.aufirst=Jessica&rft.au=Jacobs, Bret&rft.au=Silvis, Matthew&rft_id=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5753968&rfr_id=info:sid/en.wikipedia.org:Performance-enhancing substance" class="Z3988">
  25. ^ Kreider RB (February 2003). "Effects of creatine supplementation on performance and training adaptations". Molecular and Cellular Biochemistry. 244 (1–2): 89–94. doi:10.1023/A:1022465203458. ISSN 0300-8177. PMID 12701815. S2CID 35050122.1–2&rft.pages=89-94&rft.date=2003-02&rft.issn=0300-8177&rft_id=https://api.semanticscholar.org/CorpusID:35050122#id-name=S2CID&rft_id=info:pmid/12701815&rft_id=info:doi/10.1023/A:1022465203458&rft.aulast=Kreider&rft.aufirst=Richard B.&rft_id=https://pubmed.ncbi.nlm.nih.gov/12701815/&rfr_id=info:sid/en.wikipedia.org:Performance-enhancing substance" class="Z3988">
  26. ^ Francaux M, Poortmans JR (December 2006). "Side effects of creatine supplementation in athletes". International Journal of Sports Physiology and Performance. 1 (4): 311–323. doi:10.1123/ijspp.1.4.311. ISSN 1555-0265. PMID 19124889.311-323&rft.date=2006-12&rft.issn=1555-0265&rft_id=info:pmid/19124889&rft_id=info:doi/10.1123/ijspp.1.4.311&rft.aulast=Francaux&rft.aufirst=Marc&rft.au=Poortmans, Jacques R.&rft_id=https://pubmed.ncbi.nlm.nih.gov/19124889/&rfr_id=info:sid/en.wikipedia.org:Performance-enhancing substance" class="Z3988">
  27. ^ Perishable (10 March 2021). "What Do Athletes Need to Know About Creatine? | USADA". Retrieved 12 April 2022.
  28. ^ a b c d Momaya A, Fawal M, Estes R (April 2015). "Performance-enhancing substances in sports: a review of the literature". Sports Medicine. 45 (4): 517–531. doi:10.1007/s40279-015-0308-9. PMID 25663250. S2CID 45124293.517-531&rft.date=2015-04&rft_id=https://api.semanticscholar.org/CorpusID:45124293#id-name=S2CID&rft_id=info:pmid/25663250&rft_id=info:doi/10.1007/s40279-015-0308-9&rft.aulast=Momaya&rft.aufirst=A&rft.au=Fawal, M&rft.au=Estes, R&rfr_id=info:sid/en.wikipedia.org:Performance-enhancing substance" class="Z3988">
  29. ^ a b Saugy M, Robinson N, Saudan C, Baume N, Avois L, Mangin P (July 2006). "Human growth hormone doping in sport". British Journal of Sports Medicine. 40 (Suppl 1): i35 – i39. doi:10.1136/bjsm.2006.027573. ISSN 0306-3674. PMC 2657499. PMID 16799101.i35 - i39&rft.date=2006-07&rft_id=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2657499#id-name=PMC&rft.issn=0306-3674&rft_id=info:pmid/16799101&rft_id=info:doi/10.1136/bjsm.2006.027573&rft.aulast=Saugy&rft.aufirst=M&rft.au=Robinson, N&rft.au=Saudan, C&rft.au=Baume, N&rft.au=Avois, L&rft.au=Mangin, P&rft_id=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2657499&rfr_id=info:sid/en.wikipedia.org:Performance-enhancing substance" class="Z3988">
  30. ^ Laron Z (October 2001). "Insulin-like growth factor 1 (IGF-1): a growth hormone". Molecular Pathology. 54 (5): 311–316. doi:10.1136/mp.54.5.311. ISSN 1366-8714. PMC 1187088. PMID 11577173.311-316&rft.date=2001-10&rft_id=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1187088#id-name=PMC&rft.issn=1366-8714&rft_id=info:pmid/11577173&rft_id=info:doi/10.1136/mp.54.5.311&rft.aulast=Laron&rft.aufirst=Z&rft_id=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1187088&rfr_id=info:sid/en.wikipedia.org:Performance-enhancing substance" class="Z3988">
  31. ^ Siebert DM, Rao AL (October 2018). "The Use and Abuse of Human Growth Hormone in Sports". Sports Health. 10 (5): 419–426. doi:10.1177/1941738118782688. ISSN 1941-0921. PMC 6116101. PMID 29932857.419-426&rft.date=2018-10&rft_id=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6116101#id-name=PMC&rft.issn=1941-0921&rft_id=info:pmid/29932857&rft_id=info:doi/10.1177/1941738118782688&rft.aulast=Siebert&rft.aufirst=David M.&rft.au=Rao, Ashwin L.&rft_id=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6116101&rfr_id=info:sid/en.wikipedia.org:Performance-enhancing substance" class="Z3988">
  32. ^ a b Baumann GP (April 2012). "Growth hormone doping in sports: a critical review of use and detection strategies". Endocrine Reviews. 33 (2): 155–186. doi:10.1210/er.2011-1035. ISSN 1945-7189. PMID 22368183.155-186&rft.date=2012-04&rft.issn=1945-7189&rft_id=info:pmid/22368183&rft_id=info:doi/10.1210/er.2011-1035&rft.aulast=Baumann&rft.aufirst=Gerhard P.&rft_id=https://doi.org/10.1210%2Fer.2011-1035&rfr_id=info:sid/en.wikipedia.org:Performance-enhancing substance" class="Z3988">
  33. ^ Koncic MZ, Tomczyk M (August 2013). "New insights into dietary supplements used in sport: active substances, pharmacological and side effects". Current Drug Targets. 14 (9): 1079–1092. doi:10.2174/1389450111314090016. PMID 23574283.1079-1092&rft.date=2013-08&rft_id=info:doi/10.2174/1389450111314090016&rft_id=info:pmid/23574283&rft.aulast=Koncic&rft.aufirst=MZ&rft.au=Tomczyk, M&rfr_id=info:sid/en.wikipedia.org:Performance-enhancing substance" class="Z3988">
  34. ^ "Reflection Paper on the Adaptogenic Concept" (PDF). European Medicines Agency Committee on Herbal Medicinal Products. 8 May 2008. Archived from the original (PDF) on 20 September 2018. Retrieved 2 September 2018.
  35. ^ Oliynyk S, Oh S (September 2012). "The pharmacology of actoprotectors: practical application for improvement of mental and physical performance". Biomolecules & Therapeutics. 20 (5): 446–456. doi:10.4062/biomolther.2012.20.5.446. ISSN 1976-9148. PMC 3762282. PMID 24009833.446-456&rft.date=2012-09&rft_id=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3762282#id-name=PMC&rft.issn=1976-9148&rft_id=info:pmid/24009833&rft_id=info:doi/10.4062/biomolther.2012.20.5.446&rft.aulast=Oliynyk&rft.aufirst=Sergiy&rft.au=Oh, Seikwan&rft_id=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3762282&rfr_id=info:sid/en.wikipedia.org:Performance-enhancing substance" class="Z3988">
  36. ^ a b Burnat P, Payen A, Le Brumant-Payen C, Hugon M, Ceppa F (27 September 1997). "Bromontan, a new doping agent". Lancet. 350 (9082): 963–964. doi:10.1016/s0140-6736(05)63310-7. ISSN 0140-6736. PMID 9314900. S2CID 34909949.963-964&rft.date=1997-09-27&rft.issn=0140-6736&rft_id=https://api.semanticscholar.org/CorpusID:34909949#id-name=S2CID&rft_id=info:pmid/9314900&rft_id=info:doi/10.1016/s0140-6736(05)63310-7&rft.aulast=Burnat&rft.aufirst=P.&rft.au=Payen, A.&rft.au=Le Brumant-Payen, C.&rft.au=Hugon, M.&rft.au=Ceppa, F.&rft_id=https://doi.org/10.1016%2Fs0140-6736%2805%2963310-7&rfr_id=info:sid/en.wikipedia.org:Performance-enhancing substance" class="Z3988">
  37. ^ Ilieva IP, Hook CJ, Farah MJ (June 2015). "Prescription Stimulants' Effects on Healthy Inhibitory Control, Working Memory, and Episodic Memory: A Meta-analysis". Journal of Cognitive Neuroscience. 27 (6): 1069–1089. doi:10.1162/jocn_a_00776. PMID 25591060. S2CID 15788121. The present meta-analysis was conducted to estimate the magnitude of the effects of methylphenidate and amphetamine on cognitive functions central to academic and occupational functioning, including inhibitory control, working memory, short-term episodic memory, and delayed episodic memory. In addition, we examined the evidence for publication bias. Forty-eight studies (total of 1,409 participants) were included in the analyses. We found evidence for small but significant stimulant enhancement effects on inhibitory control and short-term episodic memory. Small effects on working memory reached significance, based on one of our two analytical approaches. Effects on delayed episodic memory were medium in size. However, because the effects on long-term and working memory were qualified by evidence for publication bias, we conclude that the effect of amphetamine and methylphenidate on the examined facets of healthy cognition is probably modest overall. In some situations, a small advantage may be valuable, although it is also possible that healthy users resort to stimulants to enhance their energy and motivation more than their cognition. ... Earlier research has failed to distinguish whether stimulants' effects are small or whether they are nonexistent (Ilieva et al., 2013; Smith & Farah, 2011). The present findings supported generally small effects of amphetamine and methylphenidate on executive function and memory. Specifically, in a set of experiments limited to high-quality designs, we found significant enhancement of several cognitive abilities. ...

    The results of this meta-analysis cannot address the important issues of individual differences in stimulant effects or the role of motivational enhancement in helping perform academic or occupational tasks. However, they do confirm the reality of cognitive enhancing effects for normal healthy adults in general, while also indicating that these effects are modest in size.    1069-1089&rft.date=2015-06&rft_id=https://api.semanticscholar.org/CorpusID:15788121#id-name=S2CID&rft_id=info:pmid/25591060&rft_id=info:doi/10.1162/jocn_a_00776&rft.aulast=Ilieva&rft.aufirst=IP&rft.au=Hook, CJ&rft.au=Farah, MJ&rft_id=https://repository.upenn.edu/cgi/viewcontent.cgi?article=1141&context=neuroethics_pubs&rfr_id=info:sid/en.wikipedia.org:Performance-enhancing substance" class="Z3988">
  38. ^ ""No need for laboratory to test for alcohol" – WADA". www.insidethegames.biz. 5 October 2017. Retrieved 13 October 2023.
  39. ^ a b c d Breenfeldt Andersen A, Nordsborg NB, Bonne TC, Bejder J (26 December 2022). "Contemporary blood doping—Performance, mechanism, and detection". Scandinavian Journal of Medicine & Science in Sports. 34 (1): sms.14243. doi:10.1111/sms.14243. ISSN 0905-7188. PMID 36229224. S2CID 252898039.
  40. ^ a b Mairbäurl H (12 November 2013). "Red blood cells in sports: effects of exercise and training on oxygen supply by red blood cells". Frontiers in Physiology. 4: 332. doi:10.3389/fphys.2013.00332. ISSN 1664-042X. PMC 3824146. PMID 24273518.
  41. ^ Bhoopalan SV, Huang LJ, Weiss MJ (18 September 2020). "Erythropoietin regulation of red blood cell production: from bench to bedside and back". F1000Research. 9: F1000 Faculty Rev–1153. doi:10.12688/f1000research.26648.1. ISSN 2046-1402. PMC 7503180. PMID 32983414.
  42. ^ Salamin O, Kuuranne T, Saugy M, Leuenberger N (15 March 2018). "Erythropoietin as a performance-enhancing drug: Its mechanistic basis, detection, and potential adverse effects". Molecular and Cellular Endocrinology. 464: 75–87. doi:10.1016/j.mce.2017.01.033. ISSN 1872-8057. PMID 28119134. S2CID 3441151.75-87&rft.date=2018-03-15&rft.issn=1872-8057&rft_id=https://api.semanticscholar.org/CorpusID:3441151#id-name=S2CID&rft_id=info:pmid/28119134&rft_id=info:doi/10.1016/j.mce.2017.01.033&rft.aulast=Salamin&rft.aufirst=Olivier&rft.au=Kuuranne, Tiia&rft.au=Saugy, Martial&rft.au=Leuenberger, Nicolas&rft_id=https://pubmed.ncbi.nlm.nih.gov/28119134/&rfr_id=info:sid/en.wikipedia.org:Performance-enhancing substance" class="Z3988">
  43. ^ Schumacher YO, Saugy M, Pottgiesser T, Robinson N (November 2012). "Detection of EPO doping and blood doping: the haematological module of the Athlete Biological Passport". Drug Testing and Analysis. 4 (11): 846–853. doi:10.1002/dta.406. ISSN 1942-7611. PMID 22374784.846-853&rft.date=2012-11&rft.issn=1942-7611&rft_id=info:pmid/22374784&rft_id=info:doi/10.1002/dta.406&rft.aulast=Schumacher&rft.aufirst=Yorck Olaf&rft.au=Saugy, Martial&rft.au=Pottgiesser, Torben&rft.au=Robinson, Neil&rft_id=https://pubmed.ncbi.nlm.nih.gov/22374784/&rfr_id=info:sid/en.wikipedia.org:Performance-enhancing substance" class="Z3988">
  44. ^ John R, Dhillon MS, Dhillon S (May 2020). "Genetics and the Elite Athlete: Our Understanding in 2020". Indian Journal of Orthopaedics. 54 (3): 256–263. doi:10.1007/s43465-020-00056-z. ISSN 0019-5413. PMC 7205921. PMID 32399143.256-263&rft.date=2020-05&rft_id=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7205921#id-name=PMC&rft.issn=0019-5413&rft_id=info:pmid/32399143&rft_id=info:doi/10.1007/s43465-020-00056-z&rft.aulast=John&rft.aufirst=Rakesh&rft.au=Dhillon, Mandeep Singh&rft.au=Dhillon, Sidak&rft_id=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7205921&rfr_id=info:sid/en.wikipedia.org:Performance-enhancing substance" class="Z3988">
  45. ^ a b Delbeke FT, Van Eenoo P, Van Thuyne W, Desmet N (December 2002). "Prohormones and sport". The Journal of Steroid Biochemistry and Molecular Biology. 83 (1–5): 245–251. doi:10.1016/s0960-0760(02)00274-1. ISSN 0960-0760. PMID 12650722. S2CID 46183096.1–5&rft.pages=245-251&rft.date=2002-12&rft.issn=0960-0760&rft_id=https://api.semanticscholar.org/CorpusID:46183096#id-name=S2CID&rft_id=info:pmid/12650722&rft_id=info:doi/10.1016/s0960-0760(02)00274-1&rft.aulast=Delbeke&rft.aufirst=Frans T.&rft.au=Van Eenoo, Peter&rft.au=Van Thuyne, Wim&rft.au=Desmet, Noël&rft_id=https://pubmed.ncbi.nlm.nih.gov/12650722/&rfr_id=info:sid/en.wikipedia.org:Performance-enhancing substance" class="Z3988">
  46. ^ a b Labrie F, Luu-The V, Martel C, Chernomoretz A, Calvo E, Morissette J, et al. (July 2006). "Dehydroepiandrosterone (DHEA) is an anabolic steroid like dihydrotestosterone (DHT), the most potent natural androgen, and tetrahydrogestrinone (THG)". The Journal of Steroid Biochemistry and Molecular Biology. 100 (1–3): 52–58. doi:10.1016/j.jsbmb.2006.03.006. hdl:11336/71854. ISSN 0960-0760. PMID 16797178. S2CID 11815469.1–3&rft.pages=52-58&rft.date=2006-07&rft_id=info:hdl/11336/71854&rft_id=https://api.semanticscholar.org/CorpusID:11815469#id-name=S2CID&rft_id=info:doi/10.1016/j.jsbmb.2006.03.006&rft.issn=0960-0760&rft_id=info:pmid/16797178&rft.aulast=Labrie&rft.aufirst=Fernand&rft.au=Luu-The, Van&rft.au=Martel, Céline&rft.au=Chernomoretz, Ariel&rft.au=Calvo, Ezequiel&rft.au=Morissette, Jean&rft.au=Labrie, Claude&rft_id=https://pubmed.ncbi.nlm.nih.gov/16797178/&rfr_id=info:sid/en.wikipedia.org:Performance-enhancing substance" class="Z3988">
  47. ^ Broeder CE (February 2003). "Oral andro-related prohormone supplementation: do the potential risks outweigh the benefits?". Canadian Journal of Applied Physiology. 28 (1): 102–116. doi:10.1139/h03-009. ISSN 1066-7814. PMID 12671199.102-116&rft.date=2003-02&rft.issn=1066-7814&rft_id=info:pmid/12671199&rft_id=info:doi/10.1139/h03-009&rft.aulast=Broeder&rft.aufirst=Craig E.&rft_id=https://pubmed.ncbi.nlm.nih.gov/12671199/&rfr_id=info:sid/en.wikipedia.org:Performance-enhancing substance" class="Z3988">
  48. ^ Brown GA, Vukovich M, King DS (August 2006). "Testosterone prohormone supplements". Medicine and Science in Sports and Exercise. 38 (8): 1451–1461. doi:10.1249/01.mss.0000228928.69512.2e. ISSN 0195-9131. PMID 16888459.1451-1461&rft.date=2006-08&rft.issn=0195-9131&rft_id=info:pmid/16888459&rft_id=info:doi/10.1249/01.mss.0000228928.69512.2e&rft.aulast=Brown&rft.aufirst=Gregory A.&rft.au=Vukovich, Matthew&rft.au=King, Douglas S.&rft_id=https://doi.org/10.1249%2F01.mss.0000228928.69512.2e&rfr_id=info:sid/en.wikipedia.org:Performance-enhancing substance" class="Z3988">
  49. ^ Prendergast HM, Bannen T, Erickson TB, Honore KR (March 2003). "The toxic torch of the modern Olympic Games". Veterinary and Human Toxicology. 45 (2): 97–102. PMID 12678299.97-102&rft.date=2003-03&rft_id=info:pmid/12678299&rft.aulast=Prendergast&rft.aufirst=HM&rft.au=Bannen, T&rft.au=Erickson, TB&rft.au=Honore, KR&rfr_id=info:sid/en.wikipedia.org:Performance-enhancing substance" class="Z3988">
  50. ^ Holt RI, Erotokritou-Mulligan I, Sönksen PH (August 2009). "The history of doping and growth hormone abuse in sport". Growth Hormone & IGF Research. 19 (4): 320–326. doi:10.1016/j.ghir.2009.04.009. PMID 19467612.320-326&rft.date=2009-08&rft_id=info:doi/10.1016/j.ghir.2009.04.009&rft_id=info:pmid/19467612&rft.aulast=Holt&rft.aufirst=RI&rft.au=Erotokritou-Mulligan, I&rft.au=Sönksen, PH&rfr_id=info:sid/en.wikipedia.org:Performance-enhancing substance" class="Z3988">
  51. ^ Conti AA (2010). "Doping in sports in ancient and recent times". Medicina Nei Secoli. 22 (1–3): 181–190. PMID 21560989.1–3&rft.pages=181-190&rft.date=2010&rft_id=info:pmid/21560989&rft.aulast=Conti&rft.aufirst=AA&rft_id=https://pubmed.ncbi.nlm.nih.gov/21560989&rfr_id=info:sid/en.wikipedia.org:Performance-enhancing substance" class="Z3988">
  52. ^ a b c d Yager Z, O'Dea JA (March 2014). "Relationships between body image, nutritional supplement use, and attitudes towards doping in sport among adolescent boys: implications for prevention programs". Journal of the International Society of Sports Nutrition. 11 (1): 13. doi:10.1186/1550-2783-11-13. PMC 3986904. PMID 24670105.
  53. ^ a b Baron DA, Martin DM, Abol Magd S (June 2007). "Doping in sports and its spread to at-risk populations: an international review". World Psychiatry. 6 (2): 118–123. PMC 2219897. PMID 18235871.118-123&rft.date=2007-06&rft_id=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2219897#id-name=PMC&rft_id=info:pmid/18235871&rft.aulast=Baron&rft.aufirst=DA&rft.au=Martin, DM&rft.au=Abol Magd, S&rft_id=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2219897&rfr_id=info:sid/en.wikipedia.org:Performance-enhancing substance" class="Z3988">
  54. ^ Knechtle B, Nikolaidis PT (2018). "Physiology and Pathophysiology in Ultra-Marathon Running". Frontiers in Physiology. 9: 634. doi:10.3389/fphys.2018.00634. PMC 5992463. PMID 29910741.
  55. ^ a b c Freeman ER, Bloom DA, McGuire EJ (February 2001). "A brief history of testosterone". The Journal of Urology. 165 (2): 371–373. doi:10.1097/00005392-200102000-00004. PMID 11176375.371-373&rft.date=2001-02&rft_id=info:doi/10.1097/00005392-200102000-00004&rft_id=info:pmid/11176375&rft.aulast=Freeman&rft.aufirst=ER&rft.au=Bloom, DA&rft.au=McGuire, EJ&rfr_id=info:sid/en.wikipedia.org:Performance-enhancing substance" class="Z3988">
  56. ^ Waller CC, McLeod MD (12 October 2016). "A review of designer anabolic steroids in equine sports: Designer steroids in equine sports". Drug Testing and Analysis. 9 (9): 1304–1319. doi:10.1002/dta.2112. hdl:1885/146363. PMID 27732767. S2CID 9056906.1304-1319&rft.date=2016-10-12&rft_id=info:hdl/1885/146363&rft_id=https://api.semanticscholar.org/CorpusID:9056906#id-name=S2CID&rft_id=info:pmid/27732767&rft_id=info:doi/10.1002/dta.2112&rft.aulast=Waller&rft.aufirst=Christopher C.&rft.au=McLeod, Malcolm D.&rft_id=https://doi.org/10.1002%2Fdta.2112&rfr_id=info:sid/en.wikipedia.org:Performance-enhancing substance" class="Z3988">
  57. ^ Eidelsberg J (June 1946). "Testosterone pellet implantation". The Journal of Clinical Endocrinology and Metabolism. 6 (6): 423–425. doi:10.1210/jcem-6-6-423. PMID 20988415.423-425&rft.date=1946-06&rft_id=info:doi/10.1210/jcem-6-6-423&rft_id=info:pmid/20988415&rft.aulast=Eidelsberg&rft.aufirst=J&rfr_id=info:sid/en.wikipedia.org:Performance-enhancing substance" class="Z3988">
  58. ^ National Institute on Drug Abuse. "What is the history of anabolic steroid use?". National Institute on Drug Abuse. Retrieved 5 April 2022.
  59. ^ a b Kitagawa H, Hisatsune J, Ohge H, Kutsuno S, Hara T, Masuda K, et al. (July 2021). "Implanted Port Catheter System Infection Caused by Methicillin-resistant Staphylococcus pseudintermedius ST71-SCCmec type III". Internal Medicine. 60 (14): 2337–2340. doi:10.2169/internalmedicine.5579-20. PMC 8355384. PMID 33583884.2337-2340&rft.date=2021-07&rft_id=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8355384#id-name=PMC&rft_id=info:pmid/33583884&rft_id=info:doi/10.2169/internalmedicine.5579-20&rft.aulast=Kitagawa&rft.aufirst=H&rft.au=Hisatsune, J&rft.au=Ohge, H&rft.au=Kutsuno, S&rft.au=Hara, T&rft.au=Masuda, K&rft.au=Aziz, F&rft.au=Sugai, M&rft_id=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8355384&rfr_id=info:sid/en.wikipedia.org:Performance-enhancing substance" class="Z3988">
  60. ^ a b c White ND, Noeun J (March 2017). "Performance-Enhancing Drug Use in Adolescence". American Journal of Lifestyle Medicine. 11 (2): 122–124. doi:10.1177/1559827616680593. PMC 6125030. PMID 30202322.122-124&rft.date=2017-03&rft_id=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6125030#id-name=PMC&rft_id=info:pmid/30202322&rft_id=info:doi/10.1177/1559827616680593&rft.aulast=White&rft.aufirst=ND&rft.au=Noeun, J&rft_id=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6125030&rfr_id=info:sid/en.wikipedia.org:Performance-enhancing substance" class="Z3988">
  61. ^ a b Dandoy C, Gereige RS (June 2012). "Performance-enhancing drugs". Pediatrics in Review. 33 (6): 265–271, quiz 271–272. doi:10.1542/pir.33-6-265. PMC 4528343. PMID 22659257.265-271, quiz 271-272&rft.date=2012-06&rft_id=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4528343#id-name=PMC&rft_id=info:pmid/22659257&rft_id=info:doi/10.1542/pir.33-6-265&rft.aulast=Dandoy&rft.aufirst=C&rft.au=Gereige, RS&rft_id=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4528343&rfr_id=info:sid/en.wikipedia.org:Performance-enhancing substance" class="Z3988">
  62. ^ "Performance-Enhancing Drug Resources". Drug Free Sport. Retrieved 14 April 2013.
  63. ^ "Who we are". World Anti-Doping Agency. 14 November 2013. Retrieved 3 November 2015.
  64. ^ "U.S. Anti-Doping Agency – USADA". U.S. Anti-Doping Agency (USADA). Retrieved 3 November 2015.
edit
Retrieved from "https://en.wikipedia.org/w/index.php?title=Performance-enhancing_substance&oldid=1263788535"